Results 141 to 150 of about 5,403 (175)

Bifunctional Antibodies for Radioimmunotherapy

Hybridoma, 1995
In two-step targeting technique using bifunctional antibodies, a nonradiolabeled immunoconjugate with slow uptake kinetics (several days) is initially injected, followed by a small radiolabeled hapten with fast kinetics (several hours) that binds to the bispecific immunoconjugate already taken up by the tumor target.
J F, Chatal, A, Faivre-Chauvet, M, Bardies, P, Peltier, E, Gautherot, J, Barbet   +5 more
openaire   +2 more sources

Strategies for enhancement of radioimmunotherapy

International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1991
Two new strategies for increasing tumor uptake have been investigated. First the effect of interleukin-2 (IL-2) on tumor uptake of 125I-Lym-1 antibody in nude mice was investigated. Secondly, the use of 67Cu-labeled Lym-1 was evaluated in patients. In nude mice implanted with Raji human lymphoma, a greater than 2-fold enhancement of tumor uptake of ...
G, DeNardo, S, DeNardo, D, Kukis, H, Diril, C, Suey, C, Meares   +5 more
openaire   +2 more sources

Dosimetry models for radioimmunotherapy

Medical Physics, 1988
Tumor therapy using radiolabeled antibodies presents a challenging problem in absorbed dose determination. The purpose of this study is to evaluate the effect of tumor size on the absorbed dose distribution from beta‐emitters when the radiolabeled antibody is not uniformly distributed throughout the tumor.
V K, Langmuir, R M, Sutherland
openaire   +2 more sources

The radiation biology of radioimmunotherapy

Nuclear Medicine Communications, 2003
The treatment of cancer is a wide and varied field, encompassing many methods and modalities. Radioimmunotherapy is a technique which utilizes the ablative properties of radiation by delivering radioactive particles directly to the tumour cells. This paper presents a summary of the research evidence that relates to the optimization of the effect of ...
openaire   +2 more sources

Recent developments in radioimmunotherapy

Clinical Oncology, 1994
With the advent of monoclonal antibody techniques, there has been renewed interest in RIT as a treatment modality in patients with a variety of tumour types. There has been a considerable research effort to increase understanding of the scientific basis of such therapy at all levels.
K J, Harrington, A A, Epenetos
openaire   +2 more sources

Technological Advances in Radioimmunotherapy

Clinical Oncology, 2007
Radioimmunotherapy (RIT) is a method of selectively delivering radionuclides with toxic emissions to cancer cells, while reducing the dose to normal tissues. Although primary tumours can often be treated successfully with external beam radiotherapy or surgery, metastases often escape detection and treatment, leading to therapy failure, and these can be
J L J, Dearling, R B, Pedley
openaire   +2 more sources

Future trends in radioimmunotherapy

Seminars in Oncology, 2005
Radioimmunotherapy (RIT) is currently approved in the United States only for use in low-grade follicular or transformed non-Hodgkin's lymphoma. One of the major issues in the construction of new clinical trials is deciding in which phase of disease RIT should be applied: upfront, as part of first-line treatment, in relapsed/refractory patients, in ...
openaire   +2 more sources

Radioimmunotherapy of Ovarian Cancer

Hybridoma, 1995
Despite the advances in the management of ovarian cancer, the disease remains the leading cause of death from gynecological malignancies. As it generally remains confined to the peritoneal cavity, ovarian cancer is an attractive target for radioimmunotherapy via the intraperitoneal route of administration.
K N, Syrigos, A A, Epenetos
openaire   +2 more sources

Radioimmunotherapy with engineered antibodies

Expert Opinion on Biological Therapy, 2004
Although the advent of monoclonal antibody technology in the 1970s provided the means to specifically target radioisotopes to tumours, the initial clinical evaluations of radioimmunotherapy (RAIT) were largely unsuccessful. Over the past few decades, molecular biology techniques have advanced sufficiently to allow scientists to re-engineer antibodies ...
Maria G, Russeva, Gregory P, Adams
openaire   +2 more sources

Radioimmunotherapy in Brain Tumors

2012
Gliomas and meningiomas are the most frequent primary brain tumors. Surgery, external beam radiotherapy, and chemotherapy are, at present, the essential components in the therapeutic management of malignant brain masses. Nevertheless, these methods present limitations in terms of clinical response and rate of toxicity and morbidity. Because of the need
Grana, Chiara Maria, Paganelli, Giovanni
openaire   +2 more sources